

Outbreak of SARS-CoV-2 Infections, Including COVID-19 Associated with Large Public Gatherings – Barnstable

Morbidity and Mortality Weekly Report
70, 1059-1062

DOI: [10.15585/mmwr.mm7031e2](https://doi.org/10.15585/mmwr.mm7031e2)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Practical Mitigation Strategies for Countering the Spread of Aerosolized COVID-19 Virus (SARS-CoV-2) Using Ventilation and HEPA Air Purifiers: A Literature Review. Journal of Geoscience and Environment Protection, 2021, 09, 166-197.	0.5	2
14	Children should be offered vaccination against COVID-19. LymphoSign Journal, 0, , .	0.2	0
17	How do vaccinated people spread Delta? What the science says. Nature, 2021, 596, 327-328.	27.8	23
20	SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status – Los Angeles County, California, May 1–July 25, 2021. Morbidity and Mortality Weekly Report, 2021, 70, 1170-1176.	15.1	107
22	Covid-19: How effective are vaccines against the delta variant?. BMJ, The, 2021, 374, n1960.	6.0	33
23	New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status – New York, May 3–July 25, 2021. Morbidity and Mortality Weekly Report, 2021, 70, 1150-1155.	15.1	179
26	COVID-19: The Disease, the Immunological Challenges, the Treatment with Pharmaceuticals and Low-Dose Ionizing Radiation. Cells, 2021, 10, 2212.	4.1	4
28	Advances in the computational analysis of SARS-COV2 genome. Nonlinear Dynamics, 2021, 106, 1525-1555.	5.2	6
30	Covid-19: Delta infections threaten herd immunity vaccine strategy. BMJ, The, 2021, 374, n1933.	6.0	34
32	Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance – Eight U.S. Locations, December 2020–August 2021. Morbidity and Mortality Weekly Report, 2021, 70, 1167-1169.	15.1	261
34	COVID-19 Pneumonia in Vaccinated Population: A Six Clinical and Radiological Case Series. Medicina (Lithuania), 2021, 57, 891.	2.0	12
35	Covid-19: WHO calls for booster shot ban until end of September. BMJ, The, 2021, 374, n1962.	6.0	3
36	Estimating Vaccine Efficacy Against Transmission via Effect on Viral Load. Epidemiology, 2021, 32, 820-828.	2.7	9
41	T cell immune responses to SARS-CoV-2 and variants of concern (Alpha and Delta) in infected and vaccinated individuals. Cellular and Molecular Immunology, 2021, 18, 2554-2556.	10.5	72
44	Population Immunity Against COVID-19 in the United States. Annals of Internal Medicine, 2021, 174, 1586-1591.	3.9	20
45	Outbreak Associated with SARS-CoV-2 B.1.617.2 (Delta) Variant in an Elementary School – Marin County, California, May–June 2021. Morbidity and Mortality Weekly Report, 2021, 70, 1214-1219.	15.1	101
47	Beta testing the monkey model. Nature Immunology, 2021, 22, 1201-1203.	14.5	0
48	COVID-19 Delta variants–Current status and implications as of August 2021. Precision Clinical Medicine, 2021, 4, 287-292.	3.3	18

#	ARTICLE	IF	CITATIONS
49	Variants of SARS Coronavirus-2 and Their Potential Impact on the Future of the COVID-19 Pandemic. Zoonoses, 2021, 1, .	1.1	3
50	Outbreak of SARS-CoV-2 B.1.617.2 (Delta) Variant Infections Among Incarcerated Persons in a Federal Prison â€” Texas, Julyâ€”August 2021. Morbidity and Mortality Weekly Report, 2021, 70, 1349-1354.	15.1	50
51	Immune Responses against SARS-CoV-2â€”Questions and Experiences. Biomedicines, 2021, 9, 1342.	3.2	10
53	SARS-CoV-2 Transmission to Masked and Unmasked Close Contacts of University Students with COVID-19 â€” St. Louis, Missouri, Januaryâ€”May 2021. Morbidity and Mortality Weekly Report, 2021, 70, 1245-1248.	15.1	19
56	Finding the Middle Ground with the Clinical Laboratoryâ€™s Role in SARS-CoV-2 Genomic Surveillance. Journal of Clinical Microbiology, 2021, 59, e0181621.	3.9	1
57	Breakthrough Infections with Multiple Lineages of SARS-CoV-2 Variants Reveals Continued Risk of Severe Disease in Immunosuppressed Patients. Viruses, 2021, 13, 1743.	3.3	15
58	The viral phoenix: enhanced infectivity and immunity evasion of SARS-CoV-2 variants. Environmental Chemistry Letters, 2022, 20, 1539-1544.	16.2	6
60	Nosocomial outbreak caused by the SARS-CoV-2 Delta variant in a highly vaccinated population, Israel, July 2021. Eurosurveillance, 2021, 26, .	7.0	54
62	The cell phone vibration test: A telemedicine substitute for the tuning fork test. Laryngoscope Investigative Otolaryngology, 2021, 6, 1175-1181.	1.5	3
64	Characterisation of vaccine breakthrough infections of SARS-CoV-2 Delta and Alpha variants and within-host viral load dynamics in the community, France, June to July 2021. Eurosurveillance, 2021, 26, .	7.0	46
67	New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status â€” New York, May 3â€”July 25, 2021. Morbidity and Mortality Weekly Report, 2021, 70, 1306-1311.	15.1	93
68	Safety Monitoring of an Additional Dose of COVID-19 Vaccine â€” United States, August 12â€”September 19, 2021. Morbidity and Mortality Weekly Report, 2021, 70, 1379-1384.	15.1	66
69	Fostering a deeper understanding of COVID-19-associated mucormycosis â€” A commentary on â€œThe mucormycosis coinfection in the context of global COVID-19 outbreak: A fatal addition to the pandemic spectrumâ€•(Int. J. Surg. 2021:106031). International Journal of Surgery, 2021, 94, 106110.	2.7	2
70	Mass testing of university students for covid-19. BMJ, The, 2021, 375, n2388.	6.0	10
71	An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam. EClinicalMedicine, 2021, 41, 101143.	7.1	78
72	COVID-19 Acceleration and Vaccine Status in France - Summer 2021. SSRN Electronic Journal, 0, , .	0.4	0
73	Increased risk for COVID-19 breakthrough infection in fully vaccinated patients with substance use disorders in the United States between December 2020 and August 2021. World Psychiatry, 2022, 21, 124-132.	10.4	105
74	An Antigenic Space Framework for Understanding Antibody Escape of SARS-CoV-2 Variants. Viruses, 2021, 13, 2009.	3.3	9

#	ARTICLE	IF	CITATIONS
75	Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 202-221.	6.0	569
77	Developing COVID-19 vaccine policy in increments. <i>Lancet, The</i> , 2021, 398, 1382-1383.	13.7	0
79	Attitudes about COVID-19 Testing among Black Adults in the United States. <i>Ethnicity and Disease</i> , 2021, 31, 519-526.	2.3	9
80	Secondary Cases of Delta Variant Coronavirus Disease 2019 Among Vaccinated Healthcare Workers With Breakthrough Infections is Rare. <i>Clinical Infectious Diseases</i> , 2022, 75, e895-e897.	5.8	10
81	Health and education concerns about returning to campus and online learning during the COVID-19 pandemic among US undergraduate STEM majors. <i>Journal of American College Health</i> , 2023, 71, 2604-2611.	1.5	4
83	Virality, desire and health assemblages: mapping (dis)continuities in the response to and management of HIV and COVID-19. <i>Culture, Health and Sexuality</i> , 2021, 23, 1516-1531.	1.8	4
84	Distinct neutralization profile of spike variants by antibodies induced upon <scp>SARSâ€CoV</scp>â€2 infection or vaccination. <i>American Journal of Hematology</i> , 2022, 97, E3.	4.1	12
85	COVID vaccines cut the risk of transmitting Delta â€” but not for long. <i>Nature</i> , 2021, , .	27.8	9
86	COVID-19 Mortality Risk Correlates Inversely with Vitamin D3 Status, and a Mortality Rate Close to Zero Could Theoretically Be Achieved at 50 ng/mL 25(OH)D3: Results of a Systematic Review and Meta-Analysis. <i>Nutrients</i> , 2021, 13, 3596.	4.1	60
91	In Vitro Effect of Taraxacum officinale Leaf Aqueous Extract on the Interaction between ACE2 Cell Surface Receptor and SARS-CoV-2 Spike Protein D614 and Four Mutants. <i>Pharmaceuticals</i> , 2021, 14, 1055.	3.8	13
92	Clinical and Genomic Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Diseases, 2022, 75, e774-e782.	5.8	5
95	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). <i>Journal of Hematology and Oncology</i> , 2021, 14, 168.	17.0	189
96	Targeting the Pentose Phosphate Pathway for SARS-CoV-2 Therapy. <i>Metabolites</i> , 2021, 11, 699.	2.9	25
97	Intranasal vaccination with a Newcastle disease virus-vectored vaccine protects hamsters from SARS-CoV-2 infection and disease. <i>IScience</i> , 2021, 24, 103219.	4.1	12
98	UpToDateÂ®. <i>Nurse Practitioner</i> , 2021, 46, 17-17.	0.3	5
99	What Happens to the Immune System after Vaccination or Recovery from COVID-19?. <i>Life</i> , 2021, 11, 1152.	2.4	5
100	Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. <i>Lancet Infectious Diseases, The</i> , 2022, 22, 183-195.	9.1	585
101	Scientific rationale for developing potent RBD-based vaccines targeting COVID-19. <i>Npj Vaccines</i> , 2021, 6, 128.	6.0	102

#	ARTICLE	IF	CITATIONS
102	Excess Deaths During the COVID-19 Economic Downturn. American Journal of Public Health, 2021, 111, e1-e3.	2.7	0
105	SARS-CoV-2 immunity and an overview of the COVID-19 vaccines. Medycinski Podmladak, 2021, 72, 20-29.	0.0	3
106	SARS-CoV-2 Delta (B.1.617.2) Variant: A Unique T478K Mutation in Receptor Binding Motif (RBM) of <i>Spike</i> Gene. Immune Network, 2021, 21, e32.	3.6	51
107	Understanding Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination. JAMA - Journal of the American Medical Association, 2021, 326, 2018.	7.4	64
108	SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. Science, 2022, 375, 331-336.	12.6	202
109	Should children be vaccinated against COVID-19?. Archives of Disease in Childhood, 2022, 107, e1.4-e8.	1.9	89
110	COVID-19 Breakthrough Infections and Transmission Risk: Real-World Data Analyses from Germany's Largest Public Health Department (Cologne). Vaccines, 2021, 9, 1267.	4.4	24
111	Coronavirus Disease 2019 Vaccine-Breakthrough Infections Requiring Hospitalization in Mayo Clinic Florida Through August 2021. Clinical Infectious Diseases, 2022, 75, e892-e894.	5.8	25
112	Simulation of future COVID-19 epidemic by vaccination coverage scenarios in Japan. Journal of Global Health, 2021, 11, 05025.	2.7	12
113	COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA. Blood, 2022, 139, 1588-1592.	1.4	70
115	Gut microbiome, Vitamin D, ACE2 interactions are critical factors in immune-senescence and inflammaging: key for vaccine response and severity of COVID-19 infection. Inflammation Research, 2022, 71, 13-26.	4.0	10
116	Stress of Overseas Long-Distance Care During COVID-19: Potential "CALM"ing Strategies. Frontiers in Psychiatry, 2021, 12, 734967.	2.6	1
117	Czerwone morze, czyli dominacja komunizmu we współczesnym świecie. Przegląd Bezpieczeństwa Wewnętrznego, 2021, 13, 120-145.	0.3	0
118	Rationally Designed Immunogens Enable Immune Focusing Following SARS-CoV-2 Spike Imprinting. SSRN Electronic Journal, 0, , .	0.4	0
119	SARS-CoV-2 Transmission and Prevention in the Era of the Delta Variant. SSRN Electronic Journal, 0, , .	0.4	4
120	Environmental sampling of the severe acute respiratory syndrome coronavirus 2 Delta variant in the inpatient wards of a hospital in Nanjing. Annals of Translational Medicine, 2021, 9, 0-0.	1.7	1
121	Treatment and therapeutic agents. , 2022, , 121-176.		0
122	Multistate Outbreak of SARS-CoV-2 Infections, Including Vaccine Breakthrough Infections, Associated with Large Public Gatherings, United States. Emerging Infectious Diseases, 2022, 28, 36-44.	4.3	19

#	ARTICLE	IF	CITATIONS
123	COVID-19: stigmatising the unvaccinated is not justified. Lancet, The, 2021, 398, 1871.	13.7	25
126	CoV-RBD121-NP Vaccine Candidate Protects against Symptomatic Disease following SARS-CoV-2 Challenge in K18-hACE2 Mice and Induces Protective Responses That Prevent COVID-19-Associated Immunopathology. Vaccines, 2021, 9, 1346.	4.4	3
128	SARS-CoV-2: Overview and Its Impact on Oral Health. Biomedicines, 2021, 9, 1690.	3.2	7
132	Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2. IScience, 2021, , 103379.	4.1	8
133	When Do We Need Massive Computations to Perform Detailed COVID-19 Simulations?. Advanced Theory and Simulations, 2022, 5, 2100343.	2.8	8
134	Licorice (Glycyrrhiza glabra) Extracts-Suitable Pharmacological Interventions for COVID-19? A Review. Plants, 2021, 10, 2600.	3.5	13
135	COVID-19 Incidence and hospitalization during the delta surge were inversely related to vaccination coverage among the most populous U.S. Counties. Health Policy and Technology, 2022, 11, 100583.	2.5	17
136	Lower SARS-CoV-2 viral shedding following COVID-19 vaccination among healthcare workers in Los Angeles, California. Open Forum Infectious Diseases, 2021, 8, ofab526.	0.9	5
137	Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. New England Journal of Medicine, 2021, 385, e92.	27.0	53
138	VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants. Vaccines, 2021, 9, 1409.	4.4	22
140	Agosto 2021 y la variante Delta: ¿es aceptable obligar a las personas a vacunarse contra el SARS-CoV-2?. Medicina Clínica, 2021, , .	0.6	0
142	Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection. Frontiers in Immunology, 2021, 12, 793953.	4.8	25
144	Delta Variants of SARS-CoV-2 Cause Significantly Increased Vaccine Breakthrough COVID-19 Cases in Houston, Texas. American Journal of Pathology, 2022, 192, 320-331.	3.8	90
145	Previous COVID-19 Infection and Antibody Levels After Vaccination. Frontiers in Public Health, 2021, 9, 778243.	2.7	69
146	Non-pharmaceutical interventions during the roll out of covid-19 vaccines. BMJ, The, 2021, 375, n2314.	6.0	31
148	Vaccine third dose and cancer patients: necessity or luxury?. ESMO Open, 2021, 6, 100306.	4.5	9
149	The mystery of COVID-19 reinfections: A global systematic review and meta-analysis. Annals of Medicine and Surgery, 2021, 72, 103130.	1.1	31
150	Isolation of 4000 SARS-CoV-2 shows that contagiousness is associated with viral load, not vaccine or symptomatic status. Emerging Microbes and Infections, 2021, 10, 2276-2278.	6.5	5

#	ARTICLE	IF	CITATIONS
151	Not All Covid-19 Waves are Similar: Origins, Detection and Mitigation Strategies for Simultaneous Waves. SSRN Electronic Journal, 0, , .	0.4	0
152	Transmission and containment of the SARS-CoV-2 Delta variant of concern in Guangzhou, China: A population-based study. PLoS Neglected Tropical Diseases, 2022, 16, e0010048.	3.0	25
153	Impact of Social Distancing on Intussusception Incidence in Children. Journal of Korean Medical Science, 2022, 37, e16.	2.5	4
154	Determinants and Trends of COVID-19 Vaccine Hesitancy and Vaccine Uptake in a National Cohort of US Adults: A Longitudinal Study. American Journal of Epidemiology, 2022, 191, 570-583.	3.4	53
155	Breakthrough infections with the SARS-CoV-2 Delta variant: vaccinations halved transmission risk. Public Health, 2022, 204, 40-42.	2.9	7
156	Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California. Nature Microbiology, 2022, 7, 277-288.	13.3	37
157	SARS-CoV-2 Omicron Mutation Is Faster than the Chase: Multiple Mutations on Spike/ACE2 Interaction Residues. Immune Network, 2021, 21, e38.	3.6	42
158	Delta variant of SARS-CoV-2: characteristics and implications for public health in Colombia. Revista Facultad De Medicina, 2021, 70, e97460.	0.2	1
159	Homologous and Heterologous Covid-19 Booster Vaccinations. New England Journal of Medicine, 2022, 386, 1046-1057.	27.0	418
160	A Pilot Study for the Evaluation of an Interferon Gamma Release Assay (IGRA) To Measure T-Cell Immune Responses after SARS-CoV-2 Infection or Vaccination in a Unique Cloistered Cohort. Journal of Clinical Microbiology, 2022, 60, jcm0219921.	3.9	28
161	Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection. Med, 2022, 3, 28-41.e8.	4.4	19
162	SARS-CoV-2 Virology. Infectious Disease Clinics of North America, 2022, 36, 251-265.	5.1	7
164	COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research. Blood Reviews, 2022, 54, 100931.	5.7	49
165	Bubble Strategy â€” A Practical Solution to Return to Regular Life in the Intertwined Era of Vaccine Rollouts and Virus Mutation. China CDC Weekly, 2022, 4, 71-73.	2.3	4
166	A fatal case of COVIDâ€”19 breakthrough infection due to the delta variant. Clinical Case Reports (discontinued), 2022, 10, e05232.	0.5	3
167	SARS-CoV-2 Variants, Vaccines, and Host Immunity. Frontiers in Immunology, 2021, 12, 809244.	4.8	176
168	SARS-CoV-2 Delta Variant Breakthrough Infection and Onward Secondary Transmission in Household. Journal of Korean Medical Science, 2022, 37, e12.	2.5	18
169	Solid Organ Transplantation From SARS-CoV-2â€”infected Donors to Uninfected Recipients: A Single-center Experience. Transplantation Direct, 2022, 8, e1286.	1.6	16

#	ARTICLE	IF	CITATIONS
171	Long-term, infection-acquired immunity against the SARS-CoV-2 Delta variant in a hamster model. Cell Reports, 2022, 38, 110394.	6.4	9
172	Colonial Privilege and COVID-19. International and Cultural Psychology Series, 2022, , 169-201.	0.2	2
173	Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants. Frontiers in Medicine, 2021, 8, 836826.	2.6	15
174	The Population-Wide Risk-Benefit Profile of Extending the Primary COVID-19 Vaccine Course Compared with an mRNA Booster Dose Program. Vaccines, 2022, 10, 140.	4.4	7
175	Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants. New England Journal of Medicine, 2022, 386, 744-756.	27.0	323
177	Characteristics of Reported Deaths Among Fully Vaccinated Persons With Coronavirus Disease 2019—United States, January—April 2021. Clinical Infectious Diseases, 2022, 75, e645-e652.	5.8	9
178	Assessing the impact of SARS-CoV-2 prevention measures in Austrian schools using agent-based simulations and cluster tracing data. Nature Communications, 2022, 13, 554.	12.8	18
179	COVID-19 reinfections among naturally infected and vaccinated individuals. Scientific Reports, 2022, 12, 1438.	3.3	79
180	Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients. Med, 2022, 3, 104-118.e4.	4.4	38
182	Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains. Science Translational Medicine, 2022, 14, .	12.4	55
183	SARS-CoV-2 Transmission and Prevention in the Era of the Delta Variant. Infectious Disease Clinics of North America, 2022, 36, 267-293.	5.1	10
185	Genomic, immunological, and clinical analysis of COVID-19 vaccine breakthrough infections in Beijing, China. Journal of Medical Virology, 2022, 94, 2237-2249.	5.0	13
187	Investigation of outbreak cases infected with the SARS-CoV-2 B.1.640 variant in a fully vaccinated elderly population, Normandy, France, November to December 2021. Eurosurveillance, 2022, 27, .	7.0	6
190	COVID-19 Vaccination Coverage and Vaccine Confidence by Sexual Orientation and Gender Identity — United States, August 29—October 30, 2021. Morbidity and Mortality Weekly Report, 2022, 71, 171-176.	15.1	33
191	Vaccination of COVID-19 convalescent plasma donors increases binding and neutralizing antibodies against SARS-CoV-2 variants. Transfusion, 2022, 62, 563-569.	1.6	7
192	A Global Survey of COVID-19 Vaccine Acceptance Among Healthcare Workers. Frontiers in Public Health, 2021, 9, 794673.	2.7	20
193	Decisions to attend holiday gatherings during COVID-19 and engagement in key prevention strategies: United States, January 2021. Epidemiology and Infection, 2022, 150, 1-29.	2.1	3
194	Transmission from vaccinated individuals in a large SARS-CoV-2 Delta variant outbreak. Cell, 2022, 185, 485-492.e10.	28.9	38

#	ARTICLE	IF	CITATIONS
196	Epidemiological and clinical insights from SARS-CoV-2 RT-PCR crossing threshold values, France, January to November 2020. <i>Eurosurveillance</i> , 2022, 27, .	7.0	6
197	August 2021 and the Delta variant: is mandatory vaccination of individuals against SARS-CoV-2 acceptable?. <i>Medicina Clínica (English Edition)</i> , 2022, 158, 233-233.	0.2	0
198	Experiences with public health recommendations for COVID-19: a qualitative study of diverse mothers with young children in the United States. <i>Journal of Communication in Healthcare</i> , 2022, 15, 64-73.	1.5	0
199	The Effects of Climate and Bioclimate on COVID-19 Cases in Poland. <i>Remote Sensing</i> , 2021, 13, 4946.	4.0	7
200	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Delta Outbreak Among Fully Vaccinated Nursing Home Residents Likely Initiated by a Fully Vaccinated Staff Member â€œ Connecticut, Julyâ€œAugust 2021. <i>Clinical Infectious Diseases</i> , 2022, 75, e909-e911.	5.8	6
201	The germinal centre B cell response to SARS-CoV-2. <i>Nature Reviews Immunology</i> , 2022, 22, 7-18.	22.7	150
202	Modeling for COVID-19 college reopening decisions: Cornell, a case study. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	37
203	Infection With the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Delta Variant Is Associated With Higher Recovery of Infectious Virus Compared to the Alpha Variant in Both Unvaccinated and Vaccinated Individuals. <i>Clinical Infectious Diseases</i> , 2022, 75, e715-e725.	5.8	130
208	Quantitative SARS-CoV-2 Viral-Load Curves in Paired Saliva Samples and Nasal Swabs Inform Appropriate Respiratory Sampling Site and Analytical Test Sensitivity Required for Earliest Viral Detection. <i>Journal of Clinical Microbiology</i> , 2022, 60, JCM0178521.	3.9	66
209	Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study. <i>BMJ, The</i> , 2021, 375, e068848.	6.0	180
210	Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. <i>Eurosurveillance</i> , 2021, 26, .	7.0	252
211	Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains. <i>Science Translational Medicine</i> , 2021, , eabm3302.	12.4	13
212	Insights from computational analysis: how does the SARS-CoV-2 Delta (B.1.617.2) variant hijack ACE2 more effectively?. <i>Physical Chemistry Chemical Physics</i> , 2022, , .	2.8	7
213	Serological Screening of Immunoglobulin G against SARS-CoV-2 Nucleocapsid and Spike Protein before and after Two Vaccine Doses among Healthcare Workers in Japan. <i>Tohoku Journal of Experimental Medicine</i> , 2022, , .	1.2	2
214	The long-term effectiveness of coronavirus disease 2019 (COVID-19) vaccines: A systematic literature review and meta-analysis. <i>Antimicrobial Stewardship & Healthcare Epidemiology</i> , 2022, 2, .	0.5	1
215	Misinformation and Disinformation: The Potential Disadvantages of Social Media in Infectious Disease and How to Combat Them. <i>Clinical Infectious Diseases</i> , 2022, 74, e34-e39.	5.8	15
216	Longitudinal Systemic and Mucosal Immune Responses to SARS-CoV-2 Infection. <i>Journal of Infectious Diseases</i> , 2022, 226, 1204-1214.	4.0	30
217	Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1987.	4.1	48

#	ARTICLE	IF	CITATIONS
218	<i>Notes from the Field:</i> Outbreak of COVID-19 Among a Highly Vaccinated Population Aboard a U.S. Navy Ship After a Port Visit – Reykjavik, Iceland, July 2021. Morbidity and Mortality Weekly Report, 2022, 71, 279-281.	15.1	5
219	Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study. Lancet Respiratory Medicine, 2022, 10, 557-565.	10.7	44
220	COVID-19 Recovery Patterns Across Alpha (B.1.1.7) and Delta (B.1.617.2) Variants of SARS-CoV-2. Frontiers in Immunology, 2022, 13, 812606.	4.8	15
221	Effectiveness of CoronaVac in preventing COVID-19 in healthcare workers. Human Vaccines and Immunotherapeutics, 2022, 18, 1-5.	3.3	7
222	Vaccination Against SARS-CoV-2 Is Associated With a Lower Viral Load and Likelihood of Systemic Symptoms. Open Forum Infectious Diseases, 2022, 9, ofac066.	0.9	17
224	Transmission of and Infection With COVID-19 Among Vaccinated and Unvaccinated Attendees of an Indoor Wedding Reception in Minnesota. JAMA Network Open, 2022, 5, e220536.	5.9	2
225	SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern. ELife, 2022, 11, .	6.0	26
226	T and B Cells Immune Response and the importance of vaccines Against SARS-CoV-2. Revista Bionatura, 2022, 7, 1-8.	0.4	0
227	Investigation of SARS-CoV-2 Transmission Associated With a Large Indoor Convention – New York City, November–December 2021. Morbidity and Mortality Weekly Report, 2022, 71, 243-248.	15.1	11
229	Rapid Antigen Assays for SARS-CoV-2. Clinics in Laboratory Medicine, 2022, 42, 203-222.	1.4	9
230	Viral Burden and Clearance in Asymptomatic COVID-19 Patients. Open Forum Infectious Diseases, 2022, 9, ofac126.	0.9	2
231	Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting. Cell Reports, 2022, 38, 110561.	6.4	16
232	The repeated setbacks of HIV vaccine development laid the groundwork for SARS-CoV-2 vaccines. Health Policy and Technology, 2022, 11, 100619.	2.5	7
233	Determining the reliability of rapid SARS-CoV-2 antigen detection in fully vaccinated individuals. Journal of Clinical Virology, 2022, 148, 105119.	3.1	10
234	Risk Stratification of SARS-CoV-2 Breakthrough Infections Based on an Outbreak at a Student Festive Event. Vaccines, 2022, 10, 432.	4.4	0
235	Characterization of immune responses in fully vaccinated individuals after breakthrough infection with the SARS-CoV-2 delta variant. Science Translational Medicine, 2022, 14, eabn6150.	12.4	57
236	COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective. Open Forum Infectious Diseases, 2022, 9, ofac124.	0.9	25
237	Factors associated with SARS-CoV-2 transmission in setting of high COVID-19 vaccination coverage: a case-control study. American Journal of Epidemiology, 2022, , .	3.4	2

#	ARTICLE	IF	CITATIONS
238	A Recombinant Subunit Vaccine Induces a Potent, Broadly Neutralizing, and Durable Antibody Response in Macaques against the SARS-CoV-2 P.1 (Gamma) Variant. <i>ACS Infectious Diseases</i> , 2022, 8, 825-840.	3.8	3
240	Identifying asymptomatic cases during the mass COVID-19 vaccination campaign: insights and implications for policy makers. <i>Future Virology</i> , 2022, 17, 141-144.	1.8	11
241	The Effect of COVID-19 Endemicity on the Mental Health of Health Workers. <i>Journal of the American Medical Directors Association</i> , 2022, 23, 405-413.e3.	2.5	15
243	SARS-CoV-2 Survival in Common Non-Alcoholic and Alcoholic Beverages. <i>Foods</i> , 2022, 11, 802.	4.3	4
244	Prevalence and Main Clinical Characteristics of Fully Vaccinated Patients Admitted to Hospital for Delta Variant COVID-19. <i>Frontiers in Medicine</i> , 2022, 9, 809154.	2.6	8
245	Severe Acute Respiratory Syndrome Coronavirus 2 Delta Vaccine Breakthrough Transmissibility in Alachua County, Florida. <i>Clinical Infectious Diseases</i> , 2022, 75, 1618-1627.	5.8	4
246	Airborne Transmission of SARS-CoV-2: Evidence and Implications for Engineering Controls. <i>Annual Review of Chemical and Biomolecular Engineering</i> , 2022, 13, 123-140.	6.8	11
247	Importance of Efferocytosis in COVID-19 Mortality. <i>Infection and Drug Resistance</i> , 2022, Volume 15, 995-1007.	2.7	1
248	Higher vaccination rates predict reduction in SARS-CoV-2 transmission across the United States. <i>Infection</i> , 2022, 50, 1255-1266.	4.7	6
249	Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1036-1043.	0.9	30
250	Utilization of SARS-COV-2 positive donors and recipients for Liver transplantation in the pandemic era – An evidence-based review. <i>Journal of Liver Transplantation</i> , 2022, , 100081.	0.4	2
251	A multipeptide SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	49
252	Intestinal Damage in COVID-19: SARS-CoV-2 Infection and Intestinal Thrombosis. <i>Frontiers in Microbiology</i> , 2022, 13, 860931.	3.5	15
253	Viral Load Among Vaccinated and Unvaccinated, Asymptomatic and Symptomatic Persons Infected With the SARS-CoV-2 Delta Variant. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac135.	0.9	40
254	Survey of fully vaccinated anti-â€œCOVID 19 people from June to November 2021: Single Italian center study. <i>Journal of Medical Virology</i> , 2022, 94, 2919-2920.	5.0	2
255	Combined Subcutaneous-Intranasal Immunization With Epitope-Based Antigens Elicits Binding and Neutralizing Antibody Responses in Serum and Mucosae Against PRRSV-2 and SARS-CoV-2. <i>Frontiers in Immunology</i> , 2022, 13, 848054.	4.8	0
257	High failure rate of ChAdOx1-nCoV19 immunization against asymptomatic infection in healthcare workers during a Delta variant surge. <i>Nature Communications</i> , 2022, 13, 1726.	12.8	5
258	Evasion of vaccine-induced humoral immunity by emerging sub-variants of SARS-CoV-2. <i>Future Microbiology</i> , 2022, 17, 417-424.	2.0	11

#	ARTICLE	IF	CITATIONS
259	Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US Between December 2020 and November 2021. <i>JAMA Oncology</i> , 2022, 8, 1027.	7.1	61
260	Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021. <i>Vaccine</i> , 2022, 40, 2869-2874.	3.8	26
261	Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 101-111.	4.7	76
262	Risk Prediction for Acute Kidney Injury in Patients Hospitalized With COVID-19. <i>Kidney Medicine</i> , 2022, 4, 100463.	2.0	4
263	Characteristic analysis of Omicron-included SARS-CoV-2 variants of concern. <i>MedComm</i> , 2022, 3, e129.	7.2	3
264	BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants. <i>Npj Vaccines</i> , 2022, 7, 41.	6.0	4
265	Experimental veterinary SARS-CoV-2 vaccine cross neutralization of the Delta (B.1.617.2) variant virus in cats. <i>Veterinary Microbiology</i> , 2022, 268, 109395.	1.9	6
266	Highly conserved s2m element of SARS-CoV-2 dimerizes via a kissing complex and interacts with host miRNA-1307-3p. <i>Nucleic Acids Research</i> , 2022, 50, 1017-1032.	14.5	25
267	Which Vaccine? The Cost of Religious Freedom in Vaccination Policy. <i>Journal of Bioethical Inquiry</i> , 2021, 18, 609-619.	1.5	4
268	SARS-CoV-2 Aerosol Transmission Indoors: A Closer Look at Viral Load, Infectivity, the Effectiveness of Preventive Measures and a Simple Approach for Practical Recommendations. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 220.	2.6	26
269	Considerations for the Safe Operation of Schools During the Coronavirus Pandemic. <i>Frontiers in Public Health</i> , 2021, 9, 751451.	2.7	9
270	Impact of the COVID-19 Pandemic on Public Health Surveillance and Survey Data Collections in the United States. <i>American Journal of Public Health</i> , 2021, 111, 2118-2121.	2.7	2
271	COVID-19 Testing and Case Rates and Social Contact Among Residential College Students in Connecticut During the 2020-2021 Academic Year. <i>JAMA Network Open</i> , 2021, 4, e2140602.	5.9	22
272	Harmony COVID-19: A ready-to-use kit, low-cost detector, and smartphone app for point-of-care SARS-CoV-2 RNA detection. <i>Science Advances</i> , 2021, 7, eabj1281.	10.3	35
273	Contact-Tracing Outcomes Among Household Contacts of Fully Vaccinated Coronavirus Disease 2019 (COVID-19) Patients: San Francisco, California, 29 January–2 July 2021. <i>Clinical Infectious Diseases</i> , 2022, 75, e267-e275.	5.8	12
275	Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals. , 2022, 19, 588-601.		27
276	SARS-CoV-2 Delta-variant breakthrough infections in nursing home residents at midterm after Comirnaty® COVID-19 vaccination. <i>Journal of Medical Virology</i> , 2022, 94, 3776-3782.	5.0	6
277	Epidemiological analysis of SARS-COV-2 B.1.617.2 (delta variant) transmission in an educational institute. <i>Medical Journal Armed Forces India</i> , 2022, , .	0.8	0

#	ARTICLE	IF	CITATIONS
278	Epidemiology of SARS-CoV-2 infection in nursing facilities and the impact of their clusters in a Japanese core city. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 955-961.	1.7	4
279	Stress of Overseas Long-Distance Care During COVID-19: Potential "CALM"ing Strategies. <i>Frontiers in Psychiatry</i> , 2021, 12, 734967.	2.6	2
280	COVID-19 in low-tolerance border quarantine systems: Impact of the Delta variant of SARS-CoV-2. <i>Science Advances</i> , 2022, 8, eabm3624.	10.3	10
281	SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. <i>RMD Open</i> , 2022, 8, e002187.	3.8	34
282	Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. <i>BioDrugs</i> , 2022, 36, 231-323.	4.6	24
283	Variant-specific vaccination induces systems immune responses and potent in vivo protection against SARS-CoV-2. <i>Cell Reports Medicine</i> , 2022, 3, 100634.	6.5	10
284	Would New SARS-CoV-2 Variants Change the War against COVID-19?. <i>Epidemiologia</i> , 2022, 3, 229-237.	2.2	3
285	POST VACCINATION COVID POSITIVE INPATIENTS IN A TERTIARY CARE HOSPITAL "AN ANALYSIS. , 2022, , 50-52.		0
286	Systematic on-site testing for SARS-CoV-2 infection among asymptomatic essential workers in Montr�al, Canada: a prospective observational and cost-assessment study. <i>CMAJ Open</i> , 2022, 10, E409-E419.	2.4	2
287	Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant. <i>Cell Reports</i> , 2022, 39, 110829.	6.4	214
288	Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 2068883.	3.3	44
289	Time-Dependent Increase in Susceptibility and Severity of Secondary Bacterial Infections During SARS-CoV-2. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	11
290	Potential of Endogenous Oxytocin in Endocrine Treatment and Prevention of COVID-19. <i>Frontiers in Endocrinology</i> , 2022, 13, 799521.	3.5	6
291	Making waves: Wastewater surveillance of SARS-CoV-2 in an endemic future. <i>Water Research</i> , 2022, 219, 118535.	11.3	37
292	SARS-CoV-2 RT-qPCR testing of pooled saliva samples: A case study of 824 asymptomatic individuals and a questionnaire survey in Japan. <i>PLoS ONE</i> , 2022, 17, e0263700.	2.5	0
293	Assessment of the Effectiveness of Omicron Transmission Mitigation Strategies for European Universities Using an Agent-Based Network Model. <i>Clinical Infectious Diseases</i> , 2022, 75, 2097-2103.	5.8	2
294	Continued effectiveness of COVID-19 vaccination among urban healthcare workers during delta variant predominance. <i>BMC Infectious Diseases</i> , 2022, 22, 457.	2.9	3
295	Could Social Bots™ Sentiment Engagement Shape Humans™ Sentiment on COVID-19 Vaccine Discussion on Twitter?. <i>Sustainability</i> , 2022, 14, 5566.	3.2	5

#	ARTICLE	IF	CITATIONS
296	Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study. PLoS ONE, 2022, 17, e0267824.	2.5	15
297	The unfulfilled potential of mucosal immunization. Journal of Allergy and Clinical Immunology, 2022, 150, 1-11.	2.9	11
298	Networks of necessity: Simulating COVID-19 mitigation strategies for disabled people and their caregivers. PLoS Computational Biology, 2022, 18, e1010042.	3.2	3
299	Safety & effectiveness of COVID-19 vaccines: A narrative review. Indian Journal of Medical Research, 2022, 155, 91.	1.0	22
302	Transmission and Infectious SARS-CoV-2 Shedding Kinetics in Vaccinated and Unvaccinated Individuals. JAMA Network Open, 2022, 5, e2213606.	5.9	65
303	A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding. Frontiers in Immunology, 2022, 13, .	4.8	7
304	Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities. Medical Review, 2022, 2, 169-196.	1.2	5
305	Cardiovascular Tropism and Sequelae of SARS-CoV-2 Infection. Viruses, 2022, 14, 1137.	3.3	6
306	Severe Acute Respiratory Syndrome Coronavirus 2 Incidence and Risk Factors in a National, Community-Based Prospective Cohort of US Adults. Clinical Infectious Diseases, 2023, 76, e375-e384.	5.8	9
307	Effectiveness of Heterologous Coronavirus Disease 2019 (COVID-19) Vaccine Booster Dosing in Brazilian Healthcare Workers, 2021. Clinical Infectious Diseases, 2023, 76, e360-e366.	5.8	21
308	Investigation of an outbreak of COVID-19 among U.S. military personnel and beneficiaries stationed in the Republic of Korea, June-July 2021. PLOS Global Public Health, 2022, 2, e0000236.	1.6	0
309	Are we suffering from the Peltzman effect? Risk perception among recovered and vaccinated people during the COVID-19 pandemic in Israel. Public Health, 2022, 209, 19-22.	2.9	7
310	Quality of antibiotic prescribing to children through the coronavirus disease 2019 (COVID-19) pandemic. Antimicrobial Stewardship & Healthcare Epidemiology, 2022, 2, .	0.5	3
311	Retrospective Cohort Study of the Effectiveness of the Sputnik V and EpiVacCorona Vaccines against the SARS-CoV-2 Delta Variant in Moscow (June–July 2021). Vaccines, 2022, 10, 984.	4.4	10
312	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Outbreak at a College With High Coronavirus Disease 2019 (COVID-19) Vaccination Coverage—Connecticut, August 2021–September 2021. Clinical Infectious Diseases, 2022, 75, S243-S250.	5.8	2
313	Nomogram Model for Prediction of SARS-CoV-2 Breakthrough Infection in Fujian: A Case–Control Real-World Study. Frontiers in Cellular and Infection Microbiology, 0, 12, .	3.9	2
314	Viable SARS-CoV-2 Delta variant detected in aerosols in a residential setting with a self-isolating college student with COVID-19. Journal of Aerosol Science, 2022, 165, 106038.	3.8	23
315	Biopsy channel of the endoscope as a potential source of infectious droplets during GI endoscopy. Gastrointestinal Endoscopy, 2022, 96, 764-770.	1.0	1

#	ARTICLE	IF	CITATIONS
316	Evaluation of a commercial SARS-CoV-2 multiplex PCR genotyping assay for variant identification in resource-scarce settings. PLoS ONE, 2022, 17, e0269071.	2.5	11
317	Lessons from SARS-CoV-2 and its variants (Review). Molecular Medicine Reports, 2022, 26, .	2.4	5
318	Relative effectiveness of booster vs. 2-dose mRNA Covid-19 vaccination in the Veterans Health Administration: Self-controlled risk interval analysis. Vaccine, 2022, 40, 4742-4747.	3.8	9
319	Is the COVID-19 Pandemic Over? The Current Status of Boosters, Immunosenescence, Long Haul COVID, and Systemic Complications. International Journal of Translational Medicine, 2022, 2, 230-241.	0.4	0
320	Monkeypox: Avoiding the Mistakes of Past Infectious Disease Epidemics. Annals of Internal Medicine, 2022, 175, 1177-1178.	3.9	42
322	Intranasal immunization with avian paramyxovirus type 3 expressing SARS-CoV-2 spike protein protects hamsters against SARS-CoV-2. Npj Vaccines, 2022, 7, .	6.0	7
323	Combination of Isothermal Recombinase-Aided Amplification and CRISPR-Cas12a-Mediated Assay for Rapid Detection of Major Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern. Frontiers in Microbiology, 0, 13, .	3.5	10
324	COVID-19 Variant Detection with a High-Fidelity CRISPR-Cas12 Enzyme. Journal of Clinical Microbiology, 2022, 60, .	3.9	18
325	Protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in Czechia. PLoS ONE, 2022, 17, e0270801.	2.5	18
326	<scp>COVID</scp>â€19 and plasma cells: Is there longâ€lived protection?*. Immunological Reviews, 2022, 309, 40-63.	6.0	26
327	The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	47
328	Coronaviruses. , 2023, , 277-306.		0
329	â€Donâ€™t Look Upâ€Your Scienceâ€Herd Immunity or Herd Mentality?. Microorganisms, 2022, 10, 1463.	3.6	2
330	Interferon resistance of emerging SARS-CoV-2 variants. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	63
331	A SARS-CoV-2 Negative Antigen Rapid Diagnostic in RT-qPCR Positive Samples Correlates With a Low Likelihood of Infectious Viruses in the Nasopharynx. Frontiers in Microbiology, 0, 13, .	3.5	4
332	Clinical and genomic signatures of SARS-CoV-2 Delta breakthrough infections in New York. EBioMedicine, 2022, 82, 104141.	6.1	11
333	Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2. Npj Vaccines, 2022, 7, .	6.0	23
334	SARS-CoV-2 viral load is associated with risk of transmission to household and community contacts. BMC Infectious Diseases, 2022, 22, .	2.9	14

#	ARTICLE	IF	CITATIONS
335	Global burden of SARS-CoV-2 infection, hospitalization and case fatality rate among COVID-19 vaccinated individuals and its associated factors: A systematic review and meta-analysis protocol. PLoS ONE, 2022, 17, e0272839.	2.5	5
336	Could widespread use of antiviral treatment curb the COVID-19 pandemic? A modeling study. BMC Infectious Diseases, 2022, 22, .	2.9	18
337	Hyponatremia and SARS-CoV-2 infection: A narrative review. Medicine (United States), 2022, 101, e30061.	1.0	7
338	Cross-Border Transmissions of the Delta Substrain AY.29 During Tokyo Olympic and Paralympic Games. Frontiers in Microbiology, 0, 13, .	3.5	6
339	Breath-holding physiology, radiological severity and adverse outcomes in COVID-19 patients: A prospective validation study. Respiriology, 2022, 27, 1073-1082.	2.3	1
340	The acceptance to heterologous booster vaccination of COVID-19 vaccine among HCWs and targeted population: A cross-sectional study in central China. Frontiers in Public Health, 0, 10, .	2.7	5
342	Infections with the SARS-CoV-2 Delta variant exhibit fourfold increased viral loads in the upper airways compared to Alpha or non-variants of concern. Scientific Reports, 2022, 12, .	3.3	26
343	An evaluation index system for regional mobile SARS-CoV-2 virus nucleic acid testing capacity in China: a modified Delphi consensus study. BMC Health Services Research, 2022, 22, .	2.2	0
345	Evaluation of the role of vaccination in the COVID-19 pandemic based on the data from the 50 U.S. States. Computational and Structural Biotechnology Journal, 2022, 20, 4138-4145.	4.1	2
346	SARS-CoV-2 Infection upon Leaving the Tokyo 2020 Olympic and Paralympic Games. Internal Medicine, 2022, 61, 3659-3666.	0.7	2
347	Smart and connected devices in point-of-care molecular diagnostics: what role can they play in the response to COVID-19?. Expert Review of Molecular Diagnostics, 2022, 22, 775-781.	3.1	0
348	The role of B cells in COVID-19 infection and vaccination. Frontiers in Immunology, 0, 13, .	4.8	25
349	Association of mortality and early tracheostomy in patients with COVID-19: a retrospective analysis. Scientific Reports, 2022, 12, .	3.3	4
350	Rate of True-Positive Findings of COVID-19 Typical Appearance at Chest CT per RSNA Consensus Guidelines in an Increasingly Vaccinated Population. Radiology, 2023, 306, .	7.3	7
351	Advanced Molecular Tweezers with Lipid Anchors against SARS-CoV-2 and Other Respiratory Viruses. JACS, 2022, 2, 2187-2202.	7.9	4
352	Infectious viral shedding of SARS-CoV-2 Delta following vaccination: A longitudinal cohort study. PLoS Pathogens, 2022, 18, e1010802.	4.7	27
353	COVID-19 Vaccination Breakthrough Infections in a Real-World Setting: Using Community Reporters to Evaluate Vaccine Effectiveness. Infection and Drug Resistance, 0, Volume 15, 5167-5182.	2.7	9
354	SARS-CoV-2 Infections Among Vaccinated Patients on Maintenance Dialysis, January 1-August 31, 2021, United States. Kidney360, 0, 3, 10.34067/KID.0003092022.	2.1	0

#	ARTICLE	IF	CITATIONS
355	A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part. Antimicrobial Agents and Chemotherapy, 2022, 66, .	3.2	57
356	A computer modeling method to analyze rideshare data for the surveillance of novel strains of SARS-CoV-2. Annals of Epidemiology, 2022, 76, 136-142.	1.9	2
357	A Universal Travel Risk Assessment Questionnaire: Travel Assessment During COVID-19 Pandemic and Endemicity. Military Medicine, 0, , .	0.8	0
358	Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey. Blood, 2022, 140, 2773-2787.	1.4	40
359	Pathogen evolution during vaccination campaigns. PLoS Biology, 2022, 20, e3001804.	5.6	11
360	The Receptor Binding Domain of SARS-CoV-2 Lambda Variant Has a Better Chance Than the Delta Variant in Evading BNT162b2 COVID-19 mRNA Vaccine-Induced Humoral Immunity. International Journal of Molecular Sciences, 2022, 23, 11325.	4.1	6
361	Association between Adverse Reactions and Humoral Immune Response No Longer Detectable after BNT162b2 Booster Vaccination. Vaccines, 2022, 10, 1608.	4.4	3
362	A single-administration therapeutic interfering particle reduces SARS-CoV-2 viral shedding and pathogenesis in hamsters. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	5
363	Vaccination Decreases the Infectious Viral Load of Delta Variant SARS-CoV-2 in Asymptomatic Patients. Viruses, 2022, 14, 2071.	3.3	8
364	At-home Testing and Risk Factors for Acquisition of SARS-CoV-2 Infection in a Major US Metropolitan Area. Open Forum Infectious Diseases, 0, , .	0.9	0
365	Detecting and mitigating simultaneous waves of COVID-19 infections. Scientific Reports, 2022, 12, .	3.3	1
366	New Surveillance Metrics for Alerting Community-Acquired Outbreaks of Emerging SARS-CoV-2 Variants Using Imported Case Data: Bayesian Markov Chain Monte Carlo Approach. JMIR Public Health and Surveillance, 2022, 8, e40866.	2.6	3
368	Molecular and Structural Analysis of Specific Mutations from Saudi Isolates of SARS-CoV-2 RNA-Dependent RNA Polymerase and their Implications on Protein Structure and Drug-Protein Binding. Molecules, 2022, 27, 6475.	3.8	8
369	Association of mRNA Vaccination With Clinical and Virologic Features of COVID-19 Among US Essential and Frontline Workers. JAMA - Journal of the American Medical Association, 2022, 328, 1523.	7.4	21
370	Local monitoring of SARS-CoV-2 variants in two large California counties in 2021. Scientific Reports, 2022, 12, .	3.3	0
373	The pharmaceutical industry is dangerous to health. Further proof with COVID-19. , 0, 13, 475.		2
374	Missing science: A scoping study of COVID-19 epidemiological data in the United States. PLoS ONE, 2022, 17, e0248793.	2.5	1
375	Likelihood of COVID-19 reinfection in an urban community cohort in Massachusetts. , 2022, 1, 100057.		0

#	ARTICLE	IF	CITATIONS
376	COVID-19 Trauma: The New Complex Adverse Childhood Experience. , 2022, , 177-210.		0
377	Investigation of Adverse Events Experienced by Healthcare Workers following Immunization with Homologous or Heterologous COVID-19 Booster Vaccinations. Vaccines, 2022, 10, 1869.	4.4	1
378	Enhanced virulence and waning vaccine-elicited antibodies account for breakthrough infections caused by SARS-CoV-2 delta and beyond. IScience, 2022, 25, 105507.	4.1	10
379	The Potential Protective Role of GS-441524, a Metabolite of the Prodrug Remdesivir, in Vaccine Breakthrough SARS-CoV-2 Infections. Intensive Care Research, 0, , .	0.6	0
380	SARS-CoV-2 Variants of Concern and Variations within Their Genome Architecture: Does Nucleotide Distribution and Mutation Rate Alter the Functionality and Evolution of the Virus?. Viruses, 2022, 14, 2499.	3.3	4
381	Human Coronaviruses. , 2023, , 1167-1175.e6.		0
382	Evaluation of the Effectiveness of Immunization Saint-Petersburg Population against COVID-19. Epidemiologiya I Vaktsinoprofilaktika, 2022, 21, 21-28.	0.8	1
383	The effectiveness of coronavirus disease 2019 (COVID-19) vaccine in the prevention of postâ€“COVID-19 conditions: A systematic literature review and meta-analysis. Antimicrobial Stewardship & Healthcare Epidemiology, 2022, 2, .	0.5	17
384	Projecting the COVID-19 immune landscape in Japan in the presence of waning immunity and booster vaccination. Journal of Theoretical Biology, 2023, 559, 111384.	1.7	7
385	Epidemiological and clinical characteristics of vaccinated COVID-19 patients: A meta-analysis and systematic review. International Journal of Immunopathology and Pharmacology, 2022, 36, 039463202211418.	2.1	4
386	Severe acute respiratory syndrome coronavirus 2 vaccine breakthrough infections: A single metro-based testing network experience. Frontiers in Medicine, 0, 9, .	2.6	0
387	Endemicity Is Not a Victory: The Unmitigated Downside Risks of Widespread SARS-CoV-2 Transmission. Covid, 2022, 2, 1689-1709.	1.5	3
388	Clinical Features of COVID-19, Dengue, and Influenza among Adults Presenting to Emergency Departments and Urgent Care Clinicsâ€“Puerto Rico, 2012â€“2021. American Journal of Tropical Medicine and Hygiene, 2022, , .	1.4	1
389	Advances in Next-Generation Coronavirus Vaccines in Response to Future Virus Evolution. Vaccines, 2022, 10, 2035.	4.4	3
390	Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, Julyâ€“August 2021. Vaccine, 2023, 41, 1808-1818.	3.8	3
391	Do we need nasal vaccines against COVID 19 to suppress the transmission of infections?. Microbial Biotechnology, 2023, 16, 3-14.	4.2	6
392	Guest edited collection serological study of SARS-CoV-2 antibodies in japanese cats using protein-A/G-based ELISA. BMC Veterinary Research, 2022, 18, .	1.9	1
393	Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection. Journal of Taibah University Medical Sciences, 2023, 18, 600-638.	0.9	1

#	ARTICLE	IF	CITATIONS
394	The impact of COVID-19 vaccination campaign in Hong Kong SAR China and Singapore. Infectious Disease Modelling, 2023, 8, 101-106.	1.9	5
395	Reduction in COVID-19 Vaccine Effectiveness against SARS-CoV-2 Variants in Seoul according to Age, Sex, and Symptoms: A Test-Negative Case-Control Study. International Journal of Environmental Research and Public Health, 2022, 19, 16958.	2.6	1
396	Developing mucosal vaccines for SARS-CoV-2: What will it take?. Clinical Infectious Diseases, 0, , .	5.8	0
397	Comparison of Levels of Nasal, Salivary, and Plasma Antibody to Severe Acute Respiratory Syndrome Coronavirus 2 During Natural Infection and After Vaccination. Clinical Infectious Diseases, 2023, 76, 1391-1399.	5.8	13
398	<i>In Vitro</i> Screening and MD Simulations of Thiourea Derivatives against SARS-CoV-2 in Association with Multidrug Resistance ABCB1 Transporter. ACS Omega, 2022, 7, 47671-47679.	3.5	2
399	SARS-CoV-2 infections in certain groups: A review from COVID-19 study cases. AIP Conference Proceedings, 2023, , .	0.4	0
400	SARS-CoV-2 breakthrough infections during the second wave of COVID-19 at Pune, India. Frontiers in Public Health, 0, 10, .	2.7	3
401	Aligning staff schedules, testing, and isolation reduces the risk of COVID-19 outbreaks in carceral and other congregate settings: A simulation study. PLOS Global Public Health, 2023, 3, e0001302.	1.6	1
402	Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape. Human Vaccines and Immunotherapeutics, 2023, 19, .	3.3	8
403	Response to COVID-19 in Lebanon: update, challenges and lessons learned. Epidemiology and Infection, 2023, 151, .	2.1	12
404	Infection by SARSâ€CoVâ€2 with alternate frequencies of mRNA vaccine boosting. Journal of Medical Virology, 2023, 95, .	5.0	13
405	Booster vaccination protection against SARS-CoV-2 infections in young adults during an Omicron BA.1-predominant period: A retrospective cohort study. PLoS Medicine, 2023, 20, e1004153.	8.4	2
406	Scales, Pseudoscales, the Human Factor, and a Way Forward. , 2023, , 177-224.		0
407	COVID-19 Risk Compensation? Examining Vaccination Uptake among Recovered and Classification of Breakthrough Cases. Healthcare (Switzerland), 2023, 11, 58.	2.0	2
408	Hybrid Immunity to SARS-CoV-2 from Infection and Vaccinationâ€Evidence Synthesis and Implications for New COVID-19 Vaccines. Biomedicines, 2023, 11, 370.	3.2	15
409	Effectiveness of Inactivated COVID-19 Vaccines against Delta-Variant COVID-19: Evidence from an Outbreak in Inner Mongolia Autonomous Region, China. Vaccines, 2023, 11, 292.	4.4	1
410	Comparative admission rates and infection severity of COVID-19 among unvaccinated and vaccinated patients. Journal of Investigative Medicine, 2023, 71, 329-338.	1.6	1
411	The application of artificial intelligence assurance in precision farming and agricultural economics. , 2023, , 501-529.		1

#	ARTICLE	IF	CITATIONS
412	How public health authorities can use pathogen genomics in health protection practice: a consensus-building Delphi study conducted in the United Kingdom. <i>Microbial Genomics</i> , 2023, 9, .	2.0	1
413	SARS-CoV-2 Antibody Response and Sustainability after a Third Dose of BNT162b2 in Healthcare Workers at Health Promotion Centers. <i>Viruses</i> , 2023, 15, 751.	3.3	3
414	Fidelity of Ribonucleotide Incorporation by the SARS-CoV-2 Replication Complex. <i>Journal of Molecular Biology</i> , 2023, 435, 167973.	4.2	11
415	The Effects of CoronaVac and ChAdOx1 nCoV-19 in Reducing Severe Illness in Thailand: A Retrospective Cohort Study. <i>Tropical Medicine and Infectious Disease</i> , 2023, 8, 95.	2.3	3
416	Viral Mitigation: Weak Theoretical Underpinnings. <i>Studies in Public Choice</i> , 2023, , 9-58.	0.0	0
417	SARS-CoV-2 in animals: susceptibility of animal species, risk for animal and public health, monitoring, prevention and control. <i>EFSA Journal</i> , 2023, 21, .	1.8	16
419	The change in the relationship between temperature and respiratory diseases among children in Guangzhou, China. <i>Environmental Science and Pollution Research</i> , 2023, 30, 55816-55825.	5.3	0
420	Vaccination of children against COVID-19: foreign experience (literature review). <i>Detskie Infekcii (Moskva)</i> , 2023, 22, 45-49.	0.3	0
422	The Pogo-ization of Post-Pandemic Vaccine Policy. <i>Patient</i> , 2023, 16, 179-181.	2.7	1
423	A quantitative systems pharmacology model of the pathophysiology and treatment of COVID-19 predicts optimal timing of pharmacological interventions. <i>Npj Systems Biology and Applications</i> , 2023, 9, .	3.0	3
424	Misleading Beyond Visual Tricks: How People Actually Lie with Charts. , 2023, , .		3
425	Harringtonine: A more effective antagonist for Omicron variant. <i>Biochemical Pharmacology</i> , 2023, , 115617.	4.4	0
426	From Microscopic Droplets to Macroscopic Crowds: Crossing the Scales in Models of Short-Range Respiratory Disease Transmission, with Application to COVID-19. <i>Advanced Science</i> , 0, , .	11.2	0
427	A Syndemics Approach to NCAA Collegiate Sport Participation During COVID-19. , 2023, , 569-596.		0
428	Safety and immunogenicity of heterologous boosting with orally aerosolised or intramuscular Ad5-nCoV vaccine and homologous boosting with inactivated vaccines (BBIBP-CorV or CoronaVac) in children and adolescents: a randomised, open-label, parallel-controlled, non-inferiority, single-centre study. <i>Lancet Respiratory Medicine</i> , 2023, 11, 698-708.	10.7	2
429	Preventive behavior among medical students during the COVID-19 pandemic. <i>Medicinski Podmladak</i> , 2023, 74, 64-69.	0.0	0
430	Assessment of immunoglobulin G (spike and nucleocapsid protein) response to COVID-19 vaccination in Palestine. <i>Clinical Epidemiology and Global Health</i> , 2023, 22, 101330.	1.9	0
431	Immunological responses and adverse reactions of the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare workers of Faculty of Medicine, Naresuan University. <i>Vaccine</i> , 2023, 41, 4335-4340.	3.8	0

#	ARTICLE	IF	CITATIONS
432	Blaming the unvaccinated during the COVID-19 pandemic: the roles of political ideology and risk perceptions in the USA. <i>Journal of Medical Ethics</i> , 0, , jme-2022-108825.	1.8	2
434	Longer-term effectiveness of a heterologous coronavirus disease 2019 (COVID-19) vaccine booster in healthcare workers in Brazil. <i>Antimicrobial Stewardship & Healthcare Epidemiology</i> , 2023, 3, .	0.5	0
435	Rural and urban residents' attitudes and preferences toward COVID-19 prevention behaviors in a midwestern community. <i>PLoS ONE</i> , 2023, 18, e0286953.	2.5	0
437	Severity and Vaccine Effectiveness in Patients With the Omicron Variant of COVID-19 in Suzhou: A Retrospective Single-Center Study. <i>Cureus</i> , 2023, , .	0.5	0
438	Infection and Vaccine Induced Spike Antibody Responses Against SARS-CoV-2 Variants of Concern in COVID-19-Naïve Children and Adults. <i>Journal of Clinical Immunology</i> , 0, , .	3.8	0
439	The role of vaccines in the COVID-19 pandemic: what have we learned?. <i>Seminars in Immunopathology</i> , 0, , .	6.1	13
440	Postvaccination breakthrough SARS-CoV-2 infections among adults in Malaysia and attitudes towards future vaccination. <i>Asian Pacific Journal of Tropical Medicine</i> , 2023, 16, 296-304.	0.8	0
441	SARS-CoV-2 outbreak among staff and evacuees at Operation Allies Welcome Safe Havens. <i>Public Health Nursing</i> , 0, , .	1.5	0
442	N-dihydrogalactochitosan reduces mortality in a lethal mouse model of SARS-CoV-2. <i>PLoS ONE</i> , 2023, 18, e0289139.	2.5	0
443	COVID-19 (novel SARS-CoV-2) neurological illness. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2023, , 159-179.	1.8	2
444	Protection against Severe Illness versus Immunity—Redefining Vaccine Effectiveness in the Aftermath of COVID-19. <i>Microorganisms</i> , 2023, 11, 1963.	3.6	3
445	A Flexible Regression Modeling Approach Applied to Observational Laboratory Virological Data Suggests That SARS-CoV-2 Load in Upper Respiratory Tract Samples Changes with COVID-19 Epidemiology. <i>Viruses</i> , 2023, 15, 1988.	3.3	0
446	A collaborative approach to improving representation in viral genomic surveillance. <i>PLOS Global Public Health</i> , 2023, 3, e0001935.	1.6	0
447	Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 spike ferritin nanoparticle vaccine antigen produced from two different cell lines. <i>Vaccine</i> , 2023, 41, 6502-6513.	3.8	0
448	Evolution of seroprevalence to SARS-CoV-2 in blood donors in Sarajevo Canton, Federation of Bosnia and Herzegovina: Cross-sectional and longitudinal studies. <i>Influenza and Other Respiratory Viruses</i> , 2023, 17, .	3.4	0
449	Gender differences in estimated excess mortality during the COVID-19 pandemic in Thailand. <i>BMC Public Health</i> , 2023, 23, .	2.9	1
451	Adaptive COVID-19 Mitigation Strategies: Tradeoffs between Trigger Thresholds, Response Timing, and Effectiveness. <i>MDM Policy and Practice</i> , 2023, 8, .	0.9	0
452	Fight Against the Mandatory COVID-19 Immunity Passport on Twitter: Natural Language Processing Study. <i>Journal of Medical Internet Research</i> , 0, 25, e49435.	4.3	1

#	ARTICLE	IF	CITATIONS
453	Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike protein vaccine protects hamsters against heterologous infection with Beta or Delta variants. <i>Vaccine</i> , 2023, 41, 7116-7128.	3.8	2
454	Determining the impact of vaccination on SARS-CoV-2 RT-PCR cycle threshold values and infectious viral titres. <i>Access Microbiology</i> , 2023, 5, .	0.5	0
455	Community transmission of SARS-CoV-2 during the Delta wave in New York City. <i>BMC Infectious Diseases</i> , 2023, 23, .	2.9	1
456	Inferring bacterial transmission dynamics using deep sequencing genomic surveillance data. <i>Nature Communications</i> , 2023, 14, .	12.8	0
457	Reproduction number projection for the COVID-19 pandemic. , 2023, 2023, .		0
459	A Critical Glance to Non-Pharmacological Management of Novel COVID-19 Infection. , 0, , 02-13.		0
460	An outbreak of SARS-CoV-2 in a public-facing office in England. <i>Occupational Medicine</i> , 0, , .	1.4	1
461	Phase I study, and dosing regimen selection for a pivotal COVID-19 trial of GST-HG171. <i>Antimicrobial Agents and Chemotherapy</i> , 0, , .	3.2	0
463	Unveiling asymmetric dynamics: Exploring the impact of oil price on economic growth and current account deficit: Evidence from G-7 countries. <i>Resources Policy</i> , 2024, 89, 104481.	9.6	0
464	Elaboration and Analysis of SARS-CoV-2 Data in the Frame of Occupational Safety and Health Assessment in Sustainable Engineering Systems. <i>Safety</i> , 2024, 10, 6.	1.7	0
465	Seroincidence of SARS-CoV-2 infection prior to and during the rollout of vaccines in a community-based prospective cohort of U.S. adults. <i>Scientific Reports</i> , 2024, 14, .	3.3	0
466	Does COVID-19 Vaccination Protect Contact Persons? A Systematic Review. <i>Hygiene</i> , 2024, 4, 23-48.	1.7	0
467	Breakthrough infections by SARS-CoV-2 variants boost cross-reactive hybrid immune responses in mRNA-vaccinated Golden Syrian hamsters. <i>PLoS Pathogens</i> , 2024, 20, e1011805.	4.7	1
468	The mRNA-LNP vaccines “the good, the bad and the ugly?”. <i>Frontiers in Immunology</i> , 0, 15, .	4.8	0
469	Association of Demographic, Clinical, and Vaccination Characteristics with COVID-19 Viral Load Assessed by qRT-PCR. <i>Archives of Iranian Medicine</i> , 2023, 26, 688-694.	0.6	0
470	SARS-CoV-2 Symptoms during the Omicron Surge Differ between Boosted and Vaccinated Non-Boosted Persons. <i>Vaccines</i> , 2024, 12, 327.	4.4	0